GO:1905602 positive regulation of receptor-mediated endocytosis involved in cholesterol transport: LDL Uptake Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1905602 describes the positive regulation of receptor-mediated endocytosis specifically dedicated to cholesterol transport, a process essential for cellular lipid homeostasis.
• The term encompasses activation of LDL receptor (LDLR) clustering, endocytic vesicle formation, and intracellular cholesterol delivery.
• Dysregulation of this process is linked to hypercholesterolemia, atherosclerosis, and neurodegenerative disorders.
• Key molecular players include LDLR, APOB, PCSK9, and clathrin-associated machinery.
• CRISPR knockout, point mutation, and knock-in models are powerful tools to dissect the regulatory nodes of this pathway.
• Understanding GO:1905602 provides mechanistic insight into cholesterol transport across barriers such as the blood-brain barrier.
Description
Cholesterol is an essential component of cellular membranes and a precursor for steroid hormones, bile acids, and vitamin D. Cells acquire cholesterol primarily through receptor-mediated endocytosis of low-density lipoprotein (LDL) particles, a process that is tightly regulated to maintain lipid homeostasis. The Gene Ontology term GO:1905602, positive regulation of receptor-mediated endocytosis involved in cholesterol transport, captures the regulatory events that enhance the frequency, rate, or extent of this uptake pathway. This term is critical for understanding how cells adjust cholesterol acquisition in response to metabolic demands and how defects in this regulation contribute to disease. Research into GO:1905602 has revealed that the pathway is not a simple constitutive process but is subject to multiple layers of positive regulation, including transcriptional control of the LDL receptor (LDLR), post-translational modifications, and interactions with adaptor proteins. The term also encompasses the regulation of endocytosis of LDL particles across polarized cells, such as brain capillary endothelial cells, where transcytosis delivers cholesterol to the central nervous system. For biomedical researchers, GO:1905602 provides a framework to study how genetic and pharmacological interventions modulate cholesterol uptake. This article synthesizes current knowledge on the mechanisms, key genes, and experimental models relevant to this GO term, with a focus on CRISPR-based approaches for functional validation.
positive regulation of receptor-mediated endocytosis involved in cholesterol transport At A Glance
| GO ID | GO:1905602 |
|---|---|
| GO term | positive regulation of receptor-mediated endocytosis involved in cholesterol transport |
| Ontology | biological_process |
| Synonym | activation of receptor-mediated endocytosis of LDL; positive regulation of receptor-mediated endocytosis of low-density lipoprotein particle involved in cholesterol transport; upregulation of receptor-mediated endocytosis involved in intracellular cholesterol transport |
| Major function | Enhances the uptake of cholesterol via receptor-mediated endocytosis, primarily through LDLR and related receptors. |
| Related cellular component | Clathrin-coated pits, endocytic vesicles, plasma membrane |
| Related molecular function | Ligand-receptor binding, clathrin binding, GTPase activity |
| Pathway context | Cholesterol homeostasis, lipoprotein metabolism, transcytosis across endothelial barriers |
What Is GO:1905602?
GO:1905602 is defined as any process that activates or increases the frequency, rate, or extent of receptor-mediated endocytosis involved in cholesterol transport. In simpler terms, it refers to the positive regulation of the cellular uptake of cholesterol-carrying particles, such as LDL, through specific cell-surface receptors. This term is a biological process and includes synonyms such as activation of receptor-mediated endocytosis of LDL and positive regulation of receptor-mediated endocytosis of low-density lipoprotein particle involved in cholesterol transport.
Why Is positive regulation of receptor-mediated endocytosis involved in cholesterol transport Important in Cell Biology?
GO:1905602 is important because it governs a central route for cellular cholesterol acquisition, and its dysregulation is directly implicated in cardiovascular disease and neurodegeneration. Positive regulation of LDL uptake ensures that cells meet their cholesterol needs, but excessive activation can lead to lipid accumulation and atherosclerosis. Conversely, impaired regulation in the brain may contribute to neurodegenerative conditions. Understanding this term helps researchers identify therapeutic targets and design experiments to modulate cholesterol transport.
• Maintains cellular cholesterol homeostasis by adjusting LDL uptake rates.
• Plays a key role in lipoprotein metabolism and plasma cholesterol clearance.
• Dysregulation is linked to hypercholesterolemia and atherosclerosis.
• Involved in transcytosis of LDL across the blood-brain barrier, affecting brain cholesterol supply.
• Provides a mechanistic basis for studying PCSK9 inhibitors and other lipid-lowering therapies.
• Serves as a model for receptor-mediated endocytosis regulation in polarized cells.
• Relevant to inflammation and intestinal function, as endotoxin can influence lipid transport.
• Offers targets for CRISPR-based functional genomics in metabolic diseases.
What Happens During positive regulation of receptor-mediated endocytosis involved in cholesterol transport?
Ligand Recognition and Receptor Clustering
In simple terms: The cell senses cholesterol-carrying particles and gathers receptors to capture them.
Positive regulation begins with the binding of LDL particles to LDL receptors (LDLR) on the cell surface. This binding is enhanced by factors that promote receptor clustering in clathrin-coated pits. The process is regulated by the availability of LDLR and its affinity for apolipoprotein B-100 (APOB), the main protein component of LDL. Studies in brain capillary endothelial cells have shown that LDL transcytosis involves receptor-mediated recognition and clustering, which is a prerequisite for efficient cholesterol transport.
Endocytic Vesicle Formation and Internalization
In simple terms: The cell membrane invaginates to form a vesicle that brings the particle inside.
Following receptor clustering, the plasma membrane invaginates to form clathrin-coated vesicles. Positive regulation of this step increases the rate of vesicle formation and internalization. Key proteins include clathrin, adaptor protein AP-2, and dynamin. The regulation of this stage ensures that cholesterol uptake meets cellular demand. In vitro studies using brain capillary endothelial cells demonstrated that LDL transcytosis is a regulated process that can be upregulated under specific conditions.
Intracellular Trafficking and Cholesterol Release
In simple terms: The vesicle travels inside the cell and releases cholesterol for use.
After internalization, vesicles fuse with early endosomes, where the acidic environment causes the LDL particle to dissociate from the receptor. The receptor recycles back to the plasma membrane, while the LDL particle is delivered to lysosomes for degradation and cholesterol release. Positive regulation of this pathway can enhance the efficiency of cholesterol delivery to the endoplasmic reticulum and other organelles. This step is critical for maintaining cholesterol homeostasis and is subject to feedback regulation by sterol levels.
Regulation by PCSK9 and Other Modulators
In simple terms: Other proteins can turn the uptake process up or down.
PCSK9 is a secreted protease that binds to LDLR and promotes its degradation, thereby reducing LDL uptake. Conversely, positive regulators of GO:1905602 may inhibit PCSK9 activity or enhance LDLR expression. Other modulators include IDOL, which ubiquitinates LDLR, and the SREBP pathway, which controls LDLR transcription. The balance between these regulators determines the overall rate of receptor-mediated endocytosis involved in cholesterol transport.
Key Genes Involved in GO:1905602 positive regulation of receptor-mediated endocytosis involved in cholesterol transport
The following genes and proteins are central to the positive regulation of receptor-mediated endocytosis involved in cholesterol transport.
| Gene | Major Role | Research Relevance |
|---|---|---|
| LDLR | Primary receptor for LDL; mediates binding and internalization | Mutations cause familial hypercholesterolemia; target for CRISPR knockout and knock-in studies |
| APOB | Main apolipoprotein of LDL; ligand for LDLR | Polymorphisms affect LDL levels; used in overexpression models |
| PCSK9 | Secreted protease that promotes LDLR degradation | Target of lipid-lowering drugs; knockout models reduce LDL |
| MYLIP (IDOL) | E3 ubiquitin ligase that ubiquitinates LDLR | Regulates LDLR stability; knockout increases LDL uptake |
| ARH (LDLRAP1) | Adaptor protein required for LDLR clustering in coated pits | Mutations cause autosomal recessive hypercholesterolemia |
| CLTC | Clathrin heavy chain; forms coated pits | Essential for endocytosis; knockout is lethal |
| CLTA | Clathrin light chain; regulates coated pit assembly | Modulates endocytic rate |
| AP2M1 | AP-2 complex subunit mu; binds LDLR cytoplasmic tail | Knockdown reduces LDL uptake |
| DNM2 | Dynamin 2; GTPase required for vesicle scission | Inhibition blocks endocytosis |
| SREBF2 | Transcription factor controlling LDLR expression | Overexpression increases LDL uptake |
| SCAP | SREBP cleavage-activating protein; senses sterols | Knockout deregulates LDLR |
| INSIG1 | Retains SCAP in ER when sterols high | Knockdown increases LDLR |
| HMGCR | Rate-limiting enzyme in cholesterol synthesis | Feedback regulation of LDLR |
| NPC1 | Lysosomal cholesterol transporter | Mutations cause Niemann-Pick type C |
| ABCA1 | Cholesterol efflux pump | Counterbalances LDL uptake |
| Caveolin-1 | Structural protein of caveolae; may participate in LDL uptake | Controversial role in LDL endocytosis |
| LRP1 | Receptor for multiple ligands including apoE | Mediates LDL transcytosis in brain |
How Is positive regulation of receptor-mediated endocytosis involved in cholesterol transport Regulated?
The positive regulation of receptor-mediated endocytosis involved in cholesterol transport is controlled by multiple feedback loops. The SREBP-2 pathway senses endoplasmic reticulum sterol levels and regulates LDLR transcription; when sterols are low, SREBP-2 is activated and increases LDLR expression, enhancing uptake. PCSK9 post-translationally regulates LDLR by binding to its EGF-A domain and directing it to lysosomes for degradation. IDOL (MYLIP) ubiquitinates LDLR, promoting its degradation. Additionally, inflammatory signals such as endotoxin can modulate intestinal lipid transport, potentially affecting cholesterol uptake. These regulatory mechanisms ensure that cholesterol acquisition is matched to cellular needs.
positive regulation of receptor-mediated endocytosis involved in cholesterol transport and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| LDLR | Familial hypercholesterolemia, atherosclerosis | CRISPR knockout in HepG2 cells; knock-in of patient mutations |
| PCSK9 | Hypercholesterolemia | Overexpression in hepatocytes; knockout in mice |
| APOB | Familial hypercholesterolemia | Point mutation knock-in in cell lines |
| LDLRAP1 | Autosomal recessive hypercholesterolemia | Knockout in primary lymphocytes |
| LRP1 | Alzheimer's disease, brain cholesterol transport | Endothelial cell knockout; transcytosis assays |
Familial Hypercholesterolemia and Atherosclerosis
Loss-of-function mutations in LDLR, APOB, or gain-of-function mutations in PCSK9 cause familial hypercholesterolemia, characterized by elevated plasma LDL and premature atherosclerosis. Defects in the positive regulation of receptor-mediated endocytosis involved in cholesterol transport lead to reduced LDL clearance and cholesterol accumulation in arteries. CRISPR models of these mutations are valuable for testing therapeutic strategies.
Neurodegeneration and Blood-Brain Barrier Dysfunction
Cholesterol is essential for brain function, and its transport across the blood-brain barrier is mediated by receptor-mediated endocytosis. Studies using brain capillary endothelial cells have shown that LDL transcytosis is a regulated process. Impaired regulation of this pathway may contribute to neurodegenerative diseases such as Alzheimer's disease, where cholesterol metabolism is perturbed. Targeting GO:1905602 could enhance cholesterol delivery to the brain.
Metabolic Syndrome and Inflammation
Inflammation and endotoxin exposure can alter intestinal function and lipid transport. Chronic inflammation is associated with dyslipidemia and insulin resistance, conditions that may involve altered regulation of cholesterol uptake. Understanding how inflammatory signals modulate GO:1905602 could reveal new links between metabolism and immunity.
From positive regulation of receptor-mediated endocytosis involved in cholesterol transport-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X positively regulate LDL uptake? | CRISPR knockout of gene X in HepG2 or HeLa cells followed by LDL uptake assay |
| Does a specific point mutation in LDLR affect endocytosis? | Point mutation knock-in using CRISPR in LDLR-null background |
| Can a tagged version of LDLR be used to track endocytosis? | Knock-in of fluorescent tag (e.g., GFP) at LDLR locus |
| Does overexpression of gene Y enhance cholesterol transport? | Lentiviral overexpression in cell lines |
| Which genes regulate LDL transcytosis across brain endothelium? | CRISPR library screening in hCMEC/D3 cells |
| Can PCSK9 inhibitors be tested in a human cell model? | CRISPR knockout of PCSK9 in iPSC-derived hepatocytes |
How to Study the positive regulation of receptor-mediated endocytosis involved in cholesterol transport Process
| Method | What It Measures | Typical Application |
|---|---|---|
| DiI-LDL uptake assay | Rate of LDL internalization | Screening for regulators of cholesterol uptake |
| CRISPR knockout screen | Genes required for LDL uptake | Discovery of positive regulators |
| RNA-seq | Transcriptional changes in cholesterol pathway | Evaluating SREBP target genes |
| Proteomics | Protein interactions and modifications | Identifying LDLR-associated proteins |
| Live-cell imaging | Dynamics of receptor clustering and endocytosis | Visualizing real-time uptake |
| Transcytosis assay | LDL transport across endothelial monolayers | Blood-brain barrier studies |
| Cholesterol quantification | Total and free cholesterol levels | Assessing homeostasis after perturbation |
LDL Uptake Assays
Fluorescently labeled LDL (e.g., DiI-LDL) is incubated with cells, and uptake is quantified by flow cytometry or fluorescence microscopy. This method directly measures the activity of the pathway and can be used to assess the effect of genetic perturbations. It is a standard readout for GO:1905602.
CRISPR Screening
Genome-wide CRISPR knockout or activation screens can identify positive regulators of LDL uptake. Cells are transduced with a library, selected, and subjected to LDL uptake assays followed by sequencing to identify enriched sgRNAs. This approach has uncovered novel regulators of cholesterol metabolism.
Proteomics and Interactomics
Affinity purification coupled with mass spectrometry can identify proteins that interact with LDLR or other components of the endocytic machinery. This helps map the regulatory network and identify post-translational modifications that modulate the pathway.
Imaging of Endocytic Trafficking
Live-cell imaging using fluorescently tagged LDLR and endosomal markers allows visualization of receptor clustering, internalization, and trafficking. Total internal reflection fluorescence (TIRF) microscopy is particularly useful for studying events at the plasma membrane.
How CRISPR Can Be Used to Study GO:1905602 positive regulation of receptor-mediated endocytosis involved in cholesterol transport
Knockout
CRISPR knockout of candidate positive regulators (e.g., LDLR, AP2M1) abolishes or reduces LDL uptake, confirming their necessity. Knockout of negative regulators (e.g., PCSK9, IDOL) increases uptake. These models are essential for establishing causality in GO:1905602.
Point Mutation
Introducing patient-specific point mutations (e.g., in LDLR or APOB) via CRISPR base editing or homology-directed repair allows functional assessment of variants. This helps determine whether a mutation affects receptor trafficking or ligand binding.
Knock-in
Knock-in of fluorescent tags (e.g., GFP) or epitope tags at endogenous loci enables tracking of endogenous proteins. Knock-in of disease-associated alleles creates isogenic models for drug testing. These approaches provide physiological relevance.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression can increase the levels of positive regulators, enhancing LDL uptake. This is useful for gain-of-function studies and for identifying rate-limiting steps in the pathway.
How EDITGENE Supports positive regulation of receptor-mediated endocytosis involved in cholesterol transport Research
Researchers studying positive regulation of receptor-mediated endocytosis involved in cholesterol transport-related genes often need to determine whether a candidate gene is causally involved in the pathway or merely correlated. EDITGENE provides a comprehensive suite of CRISPR services to enable precise genetic perturbations and functional validation.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of receptor-mediated endocytosis involved in cholesterol transport research.
Frequently Asked Questions About positive regulation of receptor-mediated endocytosis involved in cholesterol transport
What is GO:1905602?
GO:1905602 is a Gene Ontology term for the positive regulation of receptor-mediated endocytosis involved in cholesterol transport. It describes processes that increase the uptake of cholesterol-carrying particles like LDL.
What genes are involved in positive regulation of receptor-mediated endocytosis involved in cholesterol transport?
Key genes include LDLR, APOB, PCSK9, MYLIP (IDOL), LDLRAP1, CLTC, and SREBF2, among others.
How is receptor-mediated endocytosis of LDL regulated?
It is regulated transcriptionally by SREBP-2, post-translationally by PCSK9 and IDOL, and through feedback mechanisms sensing cellular cholesterol levels.
What diseases are associated with defects in this pathway?
Familial hypercholesterolemia, atherosclerosis, and neurodegenerative disorders such as Alzheimer's disease have been linked to dysregulation of this pathway.
What experimental models are used to study GO:1905602?
Common models include CRISPR knockout cell lines, LDL uptake assays with DiI-LDL, and transcytosis assays using brain endothelial cells.
Can CRISPR be used to study cholesterol transport?
Yes, CRISPR knockout, knock-in, and activation are powerful tools to dissect the genetic regulation of cholesterol uptake.
What is the role of PCSK9 in this process?
PCSK9 binds to LDLR and promotes its degradation, thereby reducing LDL uptake. Inhibiting PCSK9 increases receptor availability and enhances cholesterol clearance.
How does the blood-brain barrier transport cholesterol?
LDL can be transcytosed across brain capillary endothelial cells via receptor-mediated endocytosis, a process that is positively regulated.
What methods measure receptor-mediated endocytosis of LDL?
Fluorescent LDL uptake assays, live-cell imaging, and transcytosis assays are commonly used.
Why is GO:1905602 important for drug discovery?
It provides a framework for identifying targets that modulate cholesterol uptake, which is relevant for developing therapies for hypercholesterolemia and related diseases.
Conclusion
GO:1905602 encapsulates the regulatory mechanisms that enhance receptor-mediated endocytosis of cholesterol-carrying particles, a process fundamental to lipid homeostasis. Its dysregulation underlies major human diseases, making it a fertile area for therapeutic intervention. Advances in CRISPR technology now allow precise dissection of the genetic and molecular players involved, paving the way for novel treatments. EDITGENE's suite of CRISPR services supports researchers in this endeavor, from knockout to knock-in and screening.
References
- 1. Mani V et al.. 2012. Growth and Development Symposium: Endotoxin, inflammation, and intestinal function in livestock.. J Anim Sci 90(5):1452-65 PMID: 22247110
- 2. Candela P et al.. 2008. Physiological pathway for low-density lipoproteins across the blood-brain barrier: transcytosis through brain capillary endothelial cells in vitro.. Endothelium 15(5-6):254-64 PMID: 19065317
